Medicare Initiative to Lower Cost of Weight-Loss Drugs for Seniors

Millions of Medicare recipients might soon pay as little as $50 monthly for popular weight-loss drugs. This is due to a new federal initiative called the Medicare GLP-1 Bridge program, launching July 1. This program aims to increase access to a class of medications that have been too expensive for many seniors.

Why It Matters

The initiative represents a major change in Medicare drug access. Traditionally, Medicare couldn’t cover weight-loss medications. However, GLP-1 drugs are now sought after for promoting weight loss and reducing risks for chronic conditions like heart disease. Although these drugs offer health benefits, their high costs—often over $900 per month without insurance—have limited access, especially for seniors on fixed incomes. Lowering out-of-pocket costs to $50 per month could allow millions more to receive these treatments.

What to Know

Starting July 1, eligible Medicare beneficiaries with prescription drug coverage can access specific GLP-1 medications for about $50 monthly. The temporary program, administered by the Centers for Medicare & Medicaid Services (CMS), will run until December 31, 2027.

“These treatments are a significant medical advancement, but many seniors find them unaffordable,” said CMS Administrator Dr. Mehmet Oz. “The Medicare GLP-1 Bridge makes them affordable and accessible, supporting our goal of improving American health.”

GLP-1 drugs, including Wegovy, Foundayo, and Zepbound, were initially for Type 2 diabetes treatment but are now prescribed for weight loss. Experts note that the program operates outside typical Medicare channels.

“Medicare is testing whether obesity medications can benefit its participants. This program doesn’t fit into normal Part D coverage. Its $50 payments don’t count toward annual out-of-pocket totals. Post-2027 access depends on program revision or integration into Medicare,” explained Alex Beene, a financial literacy instructor for the University of Tennessee at Martin.

Who Qualifies

• Enrollment in a Medicare Part D or Medicare Advantage drug plan
• A doctor’s prescription and prior authorization
• Meeting medical criteria like obesity or related conditions

To enroll, patients should coordinate with healthcare providers who will submit necessary clinical documentation via a centralized CMS system.

What Medications Are Part of the Medicare GLP-1 Bridge Program

The program grants eligible Part D plan members access to:

• Foundayo
• Wegovy (injection or tablet)
• Zepbound (KwikPen)

How the $50 Pricing Works

The program operates independently from traditional Part D coverage rules. The $50 monthly fee is a flat copay for a 30-day supply, and these costs don’t count towards deductibles or annual out-of-pocket thresholds.

“This program allows Medicare beneficiaries access to GLP-1 medications through a monthly subscription model,” said Kevin Thompson, CEO of 9i Capital Group. “This raises questions about costs, funding, and program sustainability.”

Thompson also noted the uncertainty surrounding the long-term effects of these treatments.

“We know many users regain weight quickly after stopping the medication, suggesting a lifelong need. Financially, someone is paying, but we lack answers about post-2027 plans,” he added.

What This Means for You

If you’re on Medicare, consider the following:

• Check eligibility by consulting your doctor.
• Confirm if your needed GLP-1 medication is covered.
• Prepare for the July 1 nationwide launch.

What Happens Next

The GLP-1 Bridge is temporary and designed to inform CMS’s future policy decisions. The long-term future is uncertain. Without extension past 2027, patient access might end, reversing health improvements made during the program.

“The main concern is whether the short-term benefits in weight management can persist long-term if the program isn’t extended,” Beene said.